Mizuho Raises DexCom (NASDAQ:DXCM) Price Target to $95.00

DexCom (NASDAQ:DXCM) had its price target lifted by stock analysts at Mizuho from $90.00 to $95.00 in a research note issued on Friday,Benzinga reports. The firm presently has an “outperform” rating on the medical device company’s stock. Mizuho’s price target would suggest a potential upside of 14.01% from the company’s current price.

Other equities research analysts also recently issued research reports about the company. Robert W. Baird set a $105.00 price objective on DexCom in a report on Friday. Barclays reaffirmed an “underweight” rating and issued a $64.00 target price (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. Citigroup reiterated a “buy” rating on shares of DexCom in a research note on Friday. Raymond James Financial reissued a “strong-buy” rating and set a $94.00 price target on shares of DexCom in a research report on Friday. Finally, William Blair raised shares of DexCom to a “strong-buy” rating in a research note on Friday, May 15th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $87.75.

DexCom Trading Up 11.8%

DexCom stock traded up $8.79 during trading on Friday, hitting $83.33. The company had a trading volume of 6,836,753 shares, compared to its average volume of 5,228,691. DexCom has a 1-year low of $54.11 and a 1-year high of $87.00. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The company’s 50 day simple moving average is $72.91 and its 200-day simple moving average is $69.10. The stock has a market cap of $32.15 billion, a price-to-earnings ratio of 35.55, a price-to-earnings-growth ratio of 1.24 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. During the same period in the prior year, the firm earned $0.48 earnings per share. The firm’s revenue was up 13.1% compared to the same quarter last year. As a group, analysts expect that DexCom will post 2.57 EPS for the current fiscal year.

Insider Activity at DexCom

In other DexCom news, insider Kevin R. Sayer sold 26,759 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total value of $1,926,648.00. Following the completion of the sale, the insider owned 382,482 shares in the company, valued at approximately $27,538,704. The trade was a 6.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the sale, the executive vice president directly owned 106,353 shares of the company’s stock, valued at $8,034,969.15. The trade was a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 98,506 shares of company stock valued at $7,205,258 over the last 90 days. 0.28% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of DXCM. Reflection Asset Management purchased a new stake in shares of DexCom during the fourth quarter worth approximately $25,000. Ascentis Independent Advisors acquired a new stake in shares of DexCom during the first quarter worth $25,000. MCF Advisors LLC purchased a new position in DexCom in the 4th quarter valued at $32,000. Wellington Grp LLC grew its position in DexCom by 778.7% in the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after buying an additional 475 shares during the last quarter. Finally, DV Equities LLC acquired a new position in DexCom in the 4th quarter valued at $36,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly results exceeded expectations: DexCom reported adjusted earnings of $0.70 per share versus the $0.61 consensus estimate, while revenue rose 13.1% year over year to $1.31 billion, ahead of the $1.29 billion forecast. DexCom Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Full-year outlook was raised: Management lifted its 2026 revenue forecast to approximately $5.18 billion-$5.25 billion, reflecting sustained demand for continuous glucose monitors and confidence in continued growth. DexCom also expects nearly half of U.S. users to convert to its G7 15 Day system by year-end. DexCom Raises 2026 Revenue Outlook
• Positive Sentiment: Growth remained broad-based: Second-quarter U.S. revenue reached $933 million, up 11%, while international revenue grew substantially, supporting the company’s expansion narrative for its CGM, G7 15 Day and Stelo platforms. DexCom Raises Annual Revenue Forecast
• Positive Sentiment: Analyst sentiment improved: Wells Fargo raised its price target to $90 and maintained an overweight rating, while Benchmark raised its target to $82 and assigned a buy rating. UBS also reaffirmed its buy rating with a $96 target, adding support to the bullish reaction.
• Neutral Sentiment: Institutional positioning was mixed: Hundreds of institutions adjusted their holdings, with large additions from Wellington Management, AllianceBernstein and UBS offset by sizable reductions from Jennison Associates and Nuveen.
• Negative Sentiment: Insider activity was a cautionary signal: Company insiders reported 14 open-market sales and no purchases during the past six months. This may temper enthusiasm but was outweighed by the earnings beat and raised outlook.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.